PuSH - Publikationsserver des Helmholtz Zentrums München

Zhao, X.* ; Gabriels, R.Y.* ; Hooghiemstra, W.T.R.* ; Koller, M.* ; Meersma, G.J.* ; Buist-Homan, M.* ; Visser, L.* ; Robinson, D.J.* ; Tenditnaya, A. ; Gorpas, D. ; Ntziachristos, V. ; Karrenbeld, A.* ; Kats-Ugurlu, G.* ; Fehrmann, R.S.N.* ; Nagengast, W.B.*

Validation of novel molecular imaging targets identified by functional genomic mRNA profiling to detect dysplasia in Barrett's Esophagus.

Cancers 14:2462 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Barrett's esophagus (BE) is the precursor of esophageal adenocarcinoma (EAC). Dysplastic BE (DBE) has a higher progression risk to EAC compared to non-dysplastic BE (NDBE). However, the miss rates for the endoscopic detection of DBE remain high. Fluorescence molecular endoscopy (FME) can detect DBE and mucosal EAC by highlighting the tumor-specific expression of proteins. This study aimed to identify target proteins suitable for FME. Publicly available RNA expression profiles of EAC and NDBE were corrected by functional genomic mRNA (FGmRNA) profiling. Following a class comparison between FGmRNA profiles of EAC and NDBE, predicted, significantly upregulated genes in EAC were prioritized by a literature search. Protein expression of prioritized genes was validated by immunohistochemistry (IHC) on DBE and NDBE tissues. Near-infrared fluorescent tracers targeting the proteins were developed and evaluated ex vivo on fresh human specimens. In total, 1976 overexpressed genes were identified in EAC (n = 64) compared to NDBE (n = 66) at RNA level. Prioritization and IHC validation revealed SPARC, SULF1, PKCι, and DDR1 (all p < 0.0001) as the most attractive imaging protein targets for DBE detection. Newly developed tracers SULF1-800CW and SPARC-800CW both showed higher fluorescence intensity in DBE tissue compared to paired non-dysplastic tissue. This study identified SPARC, SULF1, PKCι, and DDR1 as promising targets for FME to differentiate DBE from NDBE tissue, for which SULF1-800CW and SPARC-800CW were successfully ex vivo evaluated. Clinical studies should further validate these findings.
Impact Factor
Scopus SNIP
Altmetric
6.575
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Barrett's Esophagus ; Esophageal Adenocarcinoma ; Fluorescent Molecular Endoscopy ; Novel Biomarkers ; Functional Genomic Mrna Profiling
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 14, Heft: 10, Seiten: , Artikelnummer: 2462 Supplement: ,
Verlag MDPI
Begutachtungsstatus Peer reviewed
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-505500-001
Förderungen European Union
Dutch Cancer Society
PubMed ID 35626066
Erfassungsdatum 2022-07-06